Ethics Board (ETB)

The BIND Ethics Board exists of the following members: Dr Kerry Woolfall (Chair), Prof Annamaria De Luca, and Sally Hofmeister. You may find below their full positions and profiles.

Ethics Board members

Professor Declan Murphy

Dr Kerry Woolfall

Position
Associate Professor/Reader of Health Research Methodology

Profile
I am a social scientist with an interest in clinical trials methodology, informed consent and bioethics. My research focusses on exploring clinicians and patient perspectives to inform the design and conduct of health research. This includes leading research and guidance to inform clinical trials without prior consent in emergency and critical care situations.

Role
Dr Woolfall is chair of the BIND ethics committee.

Isabelle Mansuy

Prof Annamaria De Luca

Position
Professor of Pharmacology at the University of Bari (Italy)

Profile
Prof Annamaria De Luca has more than 25 years experience in pre-clinical translational research in the field of neuromuscular disorders with particular attention to Duchenne muscular dystrophy. Leading her group, she conducted many pre-clinical trials with novel or repurposed drugs able to act at different level of the pathophysiological cascade in dystrophinopathies, using a multidisciplinary in vivo, in situ and ex vivo approach for monitoring neuromuscular function, as well histopathology and molecular fingerprint in skeletal muscle and other tissues. She has played and still plays an active role in establishing best guidelines and standard operating procedures for improving reliability of animal data throurgh a robust study design, in the frame of international task forces, such as TREAT-NMD. She served as reviewer, core member and Chair of TREAT-NMD advisory committee for therapeutics (TACT) during the last 12 years.

Role
Member of the Ethics Board

Isabelle Mansuy

Sally Hofmeister

Position in Organisation
Board Member World Duchenne Organization (WDO)
Duchenne CAB Coordinator

Profile
Sally Hofmeister has been involved with DMD since her fourth child was diagnosed with DMD in 1993 at the age of four. She was a founding member of the German patient organization, action benni & co, now Duchenne Deutschland, and served on its board for more than ten years, where her main responsibility was research and international representation at conferences. She has also been a member of the board of WDO since it was set up (as UPPMD) in 2007. Her main role since 2018 is setting up and running the Duchenne Community Advisory Board (CAB) as its Coordinator.

Role in the project
Member of the Ethics Board